Long-form essays on pharmaceutical regulation, MHRA parallel import licensing, the structural logic of regulated industries, and the career decisions that led to building NovaPharm Healthcare Ltd.
All Essays
Each essay is a standalone analysis — drawn from direct experience building NovaPharm Healthcare under MHRA oversight and navigating the UK pharmaceutical market.
Engineering inevitability when initial conditions are tilted against you. Covers radical acceptance of disadvantage, asymmetric bets, discipline as a competitive weapon, and why the odds are structural, not personal.
Why founders flee regulated industries — and why that exodus creates durable competitive advantage. An analysis of MHRA approval timelines, capital requirements, GDP compliance, and the structural moat of pharmaceutical distribution.
A practitioner's breakdown of pharmaceutical parallel import — the €5.5B European market, MHRA PLPI licensing mechanics, post-Brexit regulatory changes, price differential economics, and the £750M UK opportunity.
Complete List
Contact
If you found these essays useful — or want to discuss pharmaceutical strategy, investment, or partnerships — reach out directly.